INTEGRATED APPROACH TO THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER: FROM PSA SCREENING AND PROSTATE BIOPSY TO MRI, PSMA PET/CT AND RADICAL PROSTATECTOMY

Muzaffar Tukhtamishev; Mukhamedzarif Mukhamed Bakhadirhanov; Nodir Rakhimov; Shavkat Shavakhabov

Authors

Muzaffar Tukhtamishev MD, PhD Urologist, RSSPMCU, Tashkent ,Uzbekistan Author
Mukhamedzarif Mukhamed Bakhadirhanov MD, DSc Head of the Operating Department, RSSPMCU, Tashkent, Uzbekistan Author
Nodir Rakhimov MD, PhD Deputy director, RSSPMCU, Tashkent ,Uzbekistan Author
Shavkat Shavakhabov Deputy Director for Scientific Affairs, RSSPMCU, Tashkent, Uzbekistan Author

Keywords:

prostate cancer, PSA, MRI, PSMA PET/CT

Abstract

Prostate cancer diagnosis requires an integrated assessment of PSA, MRI, biopsy and PSMA PET/CT. This review summarizes the role of these methods in detecting clinically significant cancer, determining disease extent and selecting patients for radical prostatectomy. The combination of PSA-based risk assessment, multiparametric MRI and targeted biopsy improves diagnostic accuracy, while PSMA PET/CT provides additional information for staging high-risk disease. An individualized diagnostic pathway may improve treatment selection and reduce unnecessary interventions.

Downloads

Download data is not yet available.

References

1. Roobol MJ, de Vos II, Månsson M, et al. European Study of Prostate Cancer Screening—23-Year Follow-up. N Engl J Med. 2025;393(17):1669–1680.

2. European Association of Urology. EAU Guidelines on Prostate Cancer. 2026. Available from: https://uroweb.org/guidelines/prostate-cancer

3. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–822.

4. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767–1777.

5. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382:917–928.

6. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–1216.

7. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547–1558.

8. Hugosson J, Månsson M, Wallström J, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126–2137.

9. Hugosson J, Godtman RA, Wallström J, et al. Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med. 2024;391:1083–1095.

10. Woo S, Ghafoor S, Becker AS, et al. Prostate-specific membrane antigen PET for local staging of prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2021;4:703–710.

11. van Kalmthout LWM, van Melick HHE, Lavalaye J, et al. Prospective validation of gallium-68 prostate specific membrane antigen-PET/CT for primary staging of prostate cancer. J Urol. 2020;203:537–545.

12. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology. 2026.

13. American Urological Association/Society of Urologic Oncology. Early Detection of Prostate Cancer: AUA/SUO Guideline. 2023.

14. Wu Q, Bates A, Guntur P, et al. Detection rate of PSMA PET using different ligands in men with biochemical recurrent prostate cancer following radical treatment: a systematic review and meta-analysis of prospective studies. Acad Radiol. 2024;31:544–563.

15. Guo H, Zhang L, Shao Y, et al. The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis. PLoS One. 2024;19:e0301653.